These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 9074858)

  • 1. Epidemiology of non-insulin-dependent diabetes mellitus and its macrovascular complications. A basis for the development of cost-effective programs.
    Warram JH; Kopczynski J; Janka HU; Krolewski AS
    Endocrinol Metab Clin North Am; 1997 Mar; 26(1):165-88. PubMed ID: 9074858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The epidemiology and cost/effectiveness analysis of diabetic angiopathy in vascular surgery].
    Reparaz L; Martínez I; Ligero JM; Landaluce M; Galindo A; Hernández A; Jiménez Cossío JA
    Angiologia; 1992; 44(6):225-33. PubMed ID: 1285581
    [No Abstract]   [Full Text] [Related]  

  • 3. Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000.
    O'Brien JA; Patrick AR; Caro J
    Clin Ther; 2003 Mar; 25(3):1017-38. PubMed ID: 12852716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidemiology of late diabetic complications. A basis for the development and evaluation of preventive programs.
    Krolewski AS; Warram JH; Freire MB
    Endocrinol Metab Clin North Am; 1996 Jun; 25(2):217-242. PubMed ID: 8799698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular complications in relation to ethnicity in non-insulin-dependent diabetes mellitus.
    Weijers RN; Goldschmidt HM; Silberbusch J
    Eur J Clin Invest; 1997 Mar; 27(3):182-8. PubMed ID: 9088852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Undiagnosed NIDDM: clinical and public health issues.
    Harris MI
    Diabetes Care; 1993 Apr; 16(4):642-52. PubMed ID: 8462395
    [No Abstract]   [Full Text] [Related]  

  • 7. The role of obesity on development of microangiopathy in the patients with non-insulin dependent diabetes mellitus (NIDDM).
    Kitamura S
    Diabetes Res Clin Pract; 1990; 10 Suppl 1():S221-3. PubMed ID: 2286135
    [No Abstract]   [Full Text] [Related]  

  • 8. The costs of non-insulin-dependent diabetes mellitus.
    Alberti KG
    Diabet Med; 1997 Jan; 14(1):7-9. PubMed ID: 9017347
    [No Abstract]   [Full Text] [Related]  

  • 9. Implications of the diabetes control and complications trial for persons with non-insulin-dependent diabetes mellitus.
    Vinik AI; Richardson DW
    South Med J; 1997 Mar; 90(3):268-82. PubMed ID: 9076296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding type 2 diabetes mellitus and associated cardiovascular disease: linked by insulin resistance.
    Tennyson GE
    Am J Manag Care; 2002 Oct; 8(16 Suppl):S450-9. PubMed ID: 12408408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia.
    Eastman RC; Javitt JC; Herman WH; Dasbach EJ; Copley-Merriman C; Maier W; Dong F; Manninen D; Zbrozek AS; Kotsanos J; Garfield SA; Harris M
    Diabetes Care; 1997 May; 20(5):735-44. PubMed ID: 9135935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiology of cardiovascular disease in type 2 diabetes.
    Serrano Rios M
    Int J Clin Pract Suppl; 2001 Sep; (121):4-7. PubMed ID: 11594245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Total and component health care costs in a non-Medicare HMO population of patients with and without type 2 diabetes and with and without macrovascular disease.
    Gandra SR; Lawrence LW; Parasuraman BM; Darin RM; Sherman JJ; Wall JL
    J Manag Care Pharm; 2006 Sep; 12(7):546-54. PubMed ID: 16981800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-utility of empagliflozin in patients with type 2 diabetes at high cardiovascular risk.
    Nguyen E; Coleman CI; Nair S; Weeda ER
    J Diabetes Complications; 2018 Feb; 32(2):210-215. PubMed ID: 29157870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Patient classification and analysis of risk profiles for type 2 diabetics as the main focus point in practice. Results of the TEMPO study].
    Lippmann-Grob B; Bierwirth RA; Kron P; Leinhos B; Funke K; Huptas M; Grüneberg M; Weich KW; Münscher C; Potthoff F
    Dtsch Med Wochenschr; 2004 Jan; 129(3):75-81. PubMed ID: 14724780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Issues surrounding tight glycemic control in people with type 2 diabetes mellitus.
    Cerveny JD; Leder RD; Weart CW
    Ann Pharmacother; 1998 Sep; 32(9):896-905. PubMed ID: 9762378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Polish Multicenter Study on Diabetes Epidemiology (PMSDE)--1998-2000].
    Szybiński Z
    Pol Arch Med Wewn; 2001 Sep; 106(3):751-8. PubMed ID: 11928582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Steps toward the primary prevention of type II diabetes mellitus. Various epidemiological considerations].
    Flórez H
    Invest Clin; 1997 Mar; 38(1):39-52. PubMed ID: 9235072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimation of the economic and health impact of complications of type 2 diabetes mellitus in the autonomous community of Madrid (Spain).
    Arrieta F; Rubio-Terrés C; Rubio-Rodríguez D; Magaña A; Piñera M; Iglesias P; Nogales P; Calañas A; Novella B; Botella-Carretero JI; Debán C; Zamarrón I; Mora G; Balsa JA; Vázquez C;
    Endocrinol Nutr; 2014 Apr; 61(4):193-201. PubMed ID: 24440211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of exenatide twice daily vs insulin glargine as add-on therapy to oral antidiabetic agents in patients with type 2 diabetes in China.
    Gu S; Wang X; Qiao Q; Gao W; Wang J; Dong H
    Diabetes Obes Metab; 2017 Dec; 19(12):1688-1697. PubMed ID: 28452095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.